EW Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 14.45%. Edwards Lifesciences's return on equity of 46.91% beat Boston Scientific's return on equity of 9.57%.

Edwards Lifesciences has a consensus price target of $81.14, signalling upside risk potential of 3.66%. On the other hand Boston Scientific has an analysts' consensus of $117.36 which suggests that it could grow by 13.42%. Given that Boston Scientific has higher upside potential than Edwards Lifesciences, analysts believe Boston Scientific is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.108, which suggesting that the stock is 10.836% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Boston Scientific quarterly revenues of $4.7B. Edwards Lifesciences's net income of $358M is lower than Boston Scientific's net income of $674M. Notably, Edwards Lifesciences's price-to-earnings ratio is 11.18x while Boston Scientific's PE ratio is 75.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.41x versus 8.78x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 30.99%. Edwards Lifesciences's return on equity of 46.91% beat Intuitive Surgical's return on equity of 15.82%.

Edwards Lifesciences has a consensus price target of $81.14, signalling upside risk potential of 3.66%. On the other hand Intuitive Surgical has an analysts' consensus of $580.92 which suggests that it could grow by 12.49%. Given that Intuitive Surgical has higher upside potential than Edwards Lifesciences, analysts believe Intuitive Surgical is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.108, which suggesting that the stock is 10.836% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Edwards Lifesciences's net income of $358M is lower than Intuitive Surgical's net income of $698.4M. Notably, Edwards Lifesciences's price-to-earnings ratio is 11.18x while Intuitive Surgical's PE ratio is 75.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.41x versus 21.51x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 11.15%. Edwards Lifesciences's return on equity of 46.91% beat Stryker's return on equity of 14.2%.

Edwards Lifesciences has a consensus price target of $81.14, signalling upside risk potential of 3.66%. On the other hand Stryker has an analysts' consensus of $422.71 which suggests that it could grow by 7.98%. Given that Stryker has higher upside potential than Edwards Lifesciences, analysts believe Stryker is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.108, which suggesting that the stock is 10.836% more volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Stryker quarterly revenues of $5.9B. Edwards Lifesciences's net income of $358M is lower than Stryker's net income of $654M. Notably, Edwards Lifesciences's price-to-earnings ratio is 11.18x while Stryker's PE ratio is 52.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.41x versus 6.51x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 25.34% compared to Edwards Lifesciences's net margin of 9.53%. Edwards Lifesciences's return on equity of 46.91% beat Zimmer Biomet Holdings's return on equity of 7.29%.

Edwards Lifesciences has a consensus price target of $81.14, signalling upside risk potential of 3.66%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $107.64 which suggests that it could grow by 14.29%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

Edwards Lifesciences has a beta of 1.108, which suggesting that the stock is 10.836% more volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.957%.

Edwards Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 1.02% to investors and pays a quarterly dividend of $0.24 per share. Edwards Lifesciences pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences quarterly revenues are $1.4B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.9B. Edwards Lifesciences's net income of $358M is higher than Zimmer Biomet Holdings's net income of $182M. Notably, Edwards Lifesciences's price-to-earnings ratio is 11.18x while Zimmer Biomet Holdings's PE ratio is 20.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences is 8.41x versus 2.47x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.